FDA approves Agios’ AQVESME™ (mitapivat) for anemia in adults with thalassemia. It's an oral PK activator.
Agios revealed that AQVESME™ (mitapivat), an oral pyruvate kinase (PK) activator, has received approval from the U.S. FDA for the treatment of thalassemia.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments